ORYZF News and Press, Oryzon Genomics S.A. From 07/26/23

Full recruitment secures the target number of completer patients Multiple primary endpoints include reduction in agitation and aggression and overall disease improvement Topline efficacy data expected in Q1 2024 Recent predefined Interim Analysis qualified PORTICO as non...

Positive aggregate safety data from vafidemstat's PORTICO Phase IIb trial in Borderline Personality Disorder (BPD), consistent with safety data from seven completed clinical trials, supporting the drug is safe and well-tolerated Continues to enroll patients in Phase IIb EVOLUTION trial wi...

Recommendation from the independent Data Monitoring Committee (DMC) to continue the PORTICO trial based on positive safety data from the initial 167 randomized patients PORTICO plans to recruit 188 patients MADRID, Spain and BOSTON, July 05, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomic...

All resolutions were approved. 35% of the issued shares represented. MADRID, Spain and BOSTON, June 27, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases...

Comprehensively reversed disease progression symptoms in a CMT mice model Selected for an oral presentation A highly selective and safe HDAC-6 inhibitor To start IND-enabling studies soon MADRID, Spain and BOSTON, June 21, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, ...

Selected for Oral Presentation Study done in the CMT1A mouse model Supported by the CMT Research Foundation MADRID, Spain and BOSTON, May 30, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leverag...

MADRID, Spain and BOSTON, May 17, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today announced the presentation of the trial in prog...

Positive results from interim analysis of vafidemstat's PORTICO Phase IIb trial in Borderline Personality Disorder Recruiting patients in FRIDA trial with iadademstat in combination with gilteritinib in relapsed/refractory FLT3-mutant AML patients ORY-4001, a selective HDAC-6 inhi...

BioEquity Europe 2023 Foro Medcap BME 2023 VI Ibero-American Congress CEAPI 2023 BIO International Conference 2023 Jefferies Healthcare Conference 2023 MidCap Paris 2023 MADRID and BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (...

Based on interim efficacy and safety data, Independent Data Monitoring Committee recommends continuation of the trial MADRID, Spain and BOSTON, April 03, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging ...